P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens
Josep Tabernero(Deaconess Hospital), Angela Capriati(Menarini Group (Italy)), Salvatore Siena(University of Milan), Michał Kwiatek(Institute of Plant Genetics, Polish Academy of Sciences), Andrea Pellacani(Harvard University), Giuseppe Curigliano(European Institute of Oncology), Cornelis J.A. Punt(Utrecht University), Daniel H. Ahn(Mayo Clinic Hospital), Chiara Cremolini(University of Pisa), Alberto F. Sobrero(Ospedale Policlinico San Martino), Marianna Ferrara(Menarini Group (Italy)), François Ghiringhelli(Inserm), Gunnar Folprecht
Cited by 5
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k